Login to Your Account



Genentech's Shares Fall On Disappointing Avastin Sales

By Jennifer Boggs


Thursday, January 12, 2006
Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the company's shares to fall nearly 5 percent in early trading Wednesday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription